Maroun J A, Pross H F, Stewart T H, White M J, Hyslop D B
J Clin Oncol. 1984 Nov;2(11):1209-14. doi: 10.1200/JCO.1984.2.11.1209.
Fourteen patients with stages I and II non-small-cell lung carcinoma receiving adjuvant immunotherapy after surgery were studied serially for natural killer (NK) cell cytotoxicity assays. Seven patients received active nonspecific immunotherapy with Freund's complete adjuvant alone and seven patients received active specific immunotherapy with tumor-associated antigen plus Freund's complete adjuvant. Both groups were analyzed as a single group in view of the lack of any difference in the results. The results indicated that NK-cell cytotoxicity v K562 was lower in untreated patients than in normal controls, but the difference was not significant. There was no evidence of specific cytotoxicity v the lung cell line A549 in untreated patients when compared with normal controls. Compared with pretreatment values, elevated cytotoxicity v both K562 and A549 was observed at every post-treatment time point tested, and this was statistically significant at several time points by a paired t test. No specific effect was noted after immunization with lung antigen on cytotoxicity against the lung cell line A549. Other correlations studied did not show any relationship between delayed hypersensitivity skin testing or serum carcinoembryonic antigen levels and NK-cell cytotoxicity. It is concluded that NK-cell reactivity was increased nonspecifically by active specific and nonspecific immunotherapy. This increase seems to peak at the 12-month period and was significant when compared with pretreatment levels.
对14例I期和II期非小细胞肺癌患者术后接受辅助免疫治疗的情况进行了连续研究,以进行自然杀伤(NK)细胞细胞毒性测定。7例患者仅接受弗氏完全佐剂的活性非特异性免疫治疗,7例患者接受肿瘤相关抗原加弗氏完全佐剂的活性特异性免疫治疗。鉴于结果无任何差异,两组作为一个单一组进行分析。结果表明,未治疗患者中NK细胞对K562的细胞毒性低于正常对照,但差异不显著。与正常对照相比,未治疗患者中未发现对肺细胞系A549的特异性细胞毒性证据。与治疗前值相比,在每个测试的治疗后时间点均观察到对K562和A549的细胞毒性升高,并且通过配对t检验在几个时间点具有统计学意义。用肺抗原免疫后,未发现对肺细胞系A549的细胞毒性有特异性影响。所研究的其他相关性未显示迟发型超敏皮肤试验或血清癌胚抗原水平与NK细胞细胞毒性之间存在任何关系。结论是,活性特异性和非特异性免疫治疗非特异性地增加了NK细胞反应性。这种增加似乎在12个月时达到峰值,与治疗前水平相比具有显著性。